EMG
NBIX icon

Ellington Management Group’s Neurocrine Biosciences NBIX Stock Holding History

Ellington Management Group’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-3,100
Closed -$268K – 289
2020
Q1 		$268K Buy
+3,100
New +$303K 0.06% 357
2017
Q3 		– Sell
-17,100
Closed -$787K – 776
2017
Q2 		$787K Buy
17,100
+5,500
+47% +$267K 0.11% 131
2017
Q1 		$502K Buy
+11,600
New +$497K 0.02% 303
2015
Q4 		– Sell
-5,300
Closed -$211K – 732
2015
Q3 		$211K Buy
+5,300
New +$256K 0.06% 559

Other funds holding NBIX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Ellington Management Group's NBIX Position: Q2 2020 in Review

Ellington Management Group sold out of Neurocrine Biosciences (NBIX) in Q2 2020, closing a stake of 3,100 shares — an estimated $268K sold.

Ellington Management Group first reported a position in NBIX in Q3 2015 and held it in 4 quarters. The position peaked at $787K in Q2 2017. 419 funds tracked by Wall St. Rank hold NBIX as of Q2 2020.

  • Ellington Management Group reported no remaining Neurocrine Biosciences position as of Q2 2020 after selling out during the quarter.
  • Ellington Management Group sold 3,100 Neurocrine Biosciences shares in Q2 2020, an estimated $268K.
  • Ellington Management Group first reported a position in Neurocrine Biosciences in Q3 2015 and held it in 4 quarters.
  • Ellington Management Group's Neurocrine Biosciences position peaked at $787K in Q2 2017.
  • 419 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2020.

Based on Ellington Management Group's 13F filing for Q2 2020, filed 17 Aug 2020.